274 related articles for article (PubMed ID: 25463273)
1. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
2. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
3. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
4. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
6. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J
Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737
[TBL] [Abstract][Full Text] [Related]
7. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
8. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
[TBL] [Abstract][Full Text] [Related]
9. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
[TBL] [Abstract][Full Text] [Related]
10. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
11. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
[TBL] [Abstract][Full Text] [Related]
12. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
[TBL] [Abstract][Full Text] [Related]
13. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
14. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
15. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
[TBL] [Abstract][Full Text] [Related]
16. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
17. Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.
Suay-Corredera C; Pricolo MR; Herrero-Galán E; Velázquez-Carreras D; Sánchez-Ortiz D; García-Giustiniani D; Delgado J; Galano-Frutos JJ; García-Cebollada H; Vilches S; Domínguez F; Molina MS; Barriales-Villa R; Frisso G; Sancho J; Serrano L; García-Pavía P; Monserrat L; Alegre-Cebollada J
J Biol Chem; 2021 Jul; 297(1):100854. PubMed ID: 34097875
[TBL] [Abstract][Full Text] [Related]
18. The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency.
van Dijk SJ; Bezold Kooiker K; Mazzalupo S; Yang Y; Kostyukova AS; Mustacich DJ; Hoye ER; Stern JA; Kittleson MD; Harris SP
Arch Biochem Biophys; 2016 Jul; 601():133-40. PubMed ID: 26777460
[TBL] [Abstract][Full Text] [Related]
19. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
20. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
Suay-Corredera C; Alegre-Cebollada J
FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
